Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
New hit discovery service combines integrated DNA-Encoded Library screening, structural biology, biophysics, and X-ray crystallography
Collaboration aims to accelerate medicinal chemistry decision-making, reduce synthesis burden and strengthen data-secure AI adoption in drug discovery
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
Three-day programme equips CSIR researchers with advanced AI tools, molecular docking insights, and biomolecular simulation expertise
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
